Nicholas R Lenze1, Douglas Farquhar1, Siddharth Sheth2, Jose P Zevallos3, Jeffrey Blumberg1, Catherine Lumley1, Samip Patel1, Trevor Hackman1, Mark C Weissler1, Wendell G Yarbrough1,4, Adam M Zanation1, Andrew F Olshan5. 1. Department of Otolaryngology/Head and Neck Surgery, University of North Carolina School of Medicine, Chapel Hill, North Carolina, U.S.A. 2. Division of Hematology and Oncology, Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, U.S.A. 3. Department of Otolaryngology-Head & Neck Surgery, Washington University School of Medicine in St. Louis, St. Louis, Missouri, U.S.A. 4. Department of Pathology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, U.S.A. 5. Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, U.S.A.
Abstract
OBJECTIVES/HYPOTHESIS: To determine drivers of the racial disparity in stage at diagnosis and overall survival (OS) between black and white patients with HPV-negative head and neck squamous cell carcinoma (HNSCC). STUDY DESIGN: Retrospective cohort study. METHODS: Data were examined from of a population-based HNSCC study in North Carolina. Multivariable logistic regression and Cox proportional hazards models were used to assess racial disparities in stage at diagnosis and OS with sequential adjustment sets. RESULTS: A total of 340 black patients and 864 white patients diagnosed with HPV-negative HNSCC were included. In the unadjusted model, black patients had increased odds of advanced T stage at diagnosis (OR 2.0; 95% CI [1.5-2.5]) and worse OS (HR 1.3, 95% CI 1.1-1.6) compared to white patients. After adjusting for age, sex, tumor site, tobacco use, and alcohol use, the racial disparity persisted for advanced T-stage at diagnosis (OR 1.7; 95% CI [1.3-2.3]) and showed a non-significant trend for worse OS (HR 1.1, 95% CI 0.9-1.3). After adding SES to the adjustment set, the association between race and stage at diagnosis was lost (OR: 1.0; 95% CI [0.8-1.5]). Further, black patients had slightly favorable OS compared to white patients (HR 0.8, 95% CI [0.6-1.0]; P = .024). CONCLUSIONS: SES has an important contribution to the racial disparity in stage at diagnosis and OS for HPV-negative HNSCC. Low SES can serve as a target for interventions aimed at mitigating the racial disparities in head and neck cancer. LEVEL OF EVIDENCE: 4 Laryngoscope, 131:1301-1309, 2021.
OBJECTIVES/HYPOTHESIS: To determine drivers of the racial disparity in stage at diagnosis and overall survival (OS) between black and white patients with HPV-negative head and neck squamous cell carcinoma (HNSCC). STUDY DESIGN: Retrospective cohort study. METHODS: Data were examined from of a population-based HNSCC study in North Carolina. Multivariable logistic regression and Cox proportional hazards models were used to assess racial disparities in stage at diagnosis and OS with sequential adjustment sets. RESULTS: A total of 340 black patients and 864 white patients diagnosed with HPV-negative HNSCC were included. In the unadjusted model, black patients had increased odds of advanced T stage at diagnosis (OR 2.0; 95% CI [1.5-2.5]) and worse OS (HR 1.3, 95% CI 1.1-1.6) compared to white patients. After adjusting for age, sex, tumor site, tobacco use, and alcohol use, the racial disparity persisted for advanced T-stage at diagnosis (OR 1.7; 95% CI [1.3-2.3]) and showed a non-significant trend for worse OS (HR 1.1, 95% CI 0.9-1.3). After adding SES to the adjustment set, the association between race and stage at diagnosis was lost (OR: 1.0; 95% CI [0.8-1.5]). Further, black patients had slightly favorable OS compared to white patients (HR 0.8, 95% CI [0.6-1.0]; P = .024). CONCLUSIONS: SES has an important contribution to the racial disparity in stage at diagnosis and OS for HPV-negative HNSCC. Low SES can serve as a target for interventions aimed at mitigating the racial disparities in head and neck cancer. LEVEL OF EVIDENCE: 4 Laryngoscope, 131:1301-1309, 2021.
Authors: David W Baker; Julie A Gazmararian; Mark V Williams; Tracy Scott; Ruth M Parker; Diane Green; Junling Ren; Jennifer Peel Journal: Am J Public Health Date: 2002-08 Impact factor: 9.308
Authors: Lorraine R Reitzel; Nga Nguyen; Mark E Zafereo; Guojun Li; Qingyi Wei; Erich M Sturgis Journal: Health Place Date: 2012-03-14 Impact factor: 4.078
Authors: Carole Fakhry; William H Westra; Steven J Wang; Annemieke van Zante; Yuehan Zhang; Eleni Rettig; Linda X Yin; William R Ryan; Patrick K Ha; Alicia Wentz; Wayne Koch; Jeremy D Richmon; David W Eisele; Gypsyamber D'Souza Journal: Cancer Date: 2017-02-27 Impact factor: 6.860
Authors: André Lopes Carvalho; Inês Nobuko Nishimoto; Joseph A Califano; Luiz Paulo Kowalski Journal: Int J Cancer Date: 2005-05-01 Impact factor: 7.396
Authors: Dan P Zandberg; Sandy Liu; Olga Goloubeva; Robert Ord; Scott E Strome; Mohan Suntharalingam; Rodney Taylor; Robert E Morales; Jeffrey S Wolf; Ann Zimrin; Joshua E Lubek; Lisa M Schumaker; Kevin J Cullen Journal: Head Neck Date: 2015-06-30 Impact factor: 3.147
Authors: Manuel A Molina; Michael C Cheung; Eduardo A Perez; Margaret M Byrne; Dido Franceschi; Frederick L Moffat; Alan S Livingstone; W Jarrard Goodwin; Juan C Gutierrez; Leonidas G Koniaris Journal: Cancer Date: 2008-11-15 Impact factor: 6.860
Authors: L Giraldi; E Leoncini; R Pastorino; V Wünsch-Filho; M de Carvalho; R Lopez; G Cadoni; D Arzani; L Petrelli; K Matsuo; C Bosetti; C La Vecchia; W Garavello; J Polesel; D Serraino; L Simonato; C Canova; L Richiardi; P Boffetta; M Hashibe; Y C A Lee; S Boccia Journal: Ann Oncol Date: 2017-11-01 Impact factor: 32.976
Authors: Ohad Ronen; K Thomas Robbins; Remco de Bree; Orlando Guntinas-Lichius; Dana M Hartl; Akihiro Homma; Avi Khafif; Luiz P Kowalski; Fernando López; Antti A Mäkitie; Wai Tong Ng; Alessandra Rinaldo; Juan P Rodrigo; Alvaro Sanabria; Alfio Ferlito Journal: Eur Arch Otorhinolaryngol Date: 2021-05-12 Impact factor: 2.503
Authors: Nicholas R Lenze; Douglas R Farquhar; Siddharth Sheth; Jose P Zevallos; Catherine Lumley; Jeffrey Blumberg; Samip Patel; Trevor Hackman; Mark C Weissler; Wendell G Yarbrough; Andrew F Olshan; Adam M Zanation Journal: Oral Oncol Date: 2021-06-20 Impact factor: 5.972